NCT04948697

A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC

A Phase 2, Randomized, Open-labeled Clinical Study Investigating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab Plus BAT1706 and of Tislelizumab Plus BAT1706 as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 94 (actual)
• Sponsor: BeiGene · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This was a Phase 2, randomized, multicenter, open-label, 2-arm study to investigate the efficacy and safety of ociperlimab in combination with tislelizumab plus BAT1706, and tislelizumab plus BAT1706, as first-line treatment in participants with advanced Hepatocellular Carcinoma (HCC).

Conditions

• Advanced Hepatocellular Carcinoma

Interventions

Type	Name	Description
DRUG	Ociperlimab	900 mg intravenously once every 3 weeks (dosed in 21-day cycles)
DRUG	Tislelizumab	200 mg intravenously once every 3 weeks (dosed in 21-day cycles)
DRUG	BAT1706	15 mg/kg intravenously once every 3 weeks (dosed in 21-day cycles)

Timeline

• Start date: 2021-08-20
• Primary completion: 2024-02-01
• Completion: 2024-02-01
• First posted: 2021-07-02
• Last updated: 2025-02-24
• Results posted: 2025-02-24

Locations

28 sites across 2 countries: China, Taiwan